Evolus (EOLS) Competitors $6.48 -0.03 (-0.38%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. VCEL, AVDL, GPCR, SDGR, ABCL, JANX, RCUS, SNDX, ARDX, and STOKShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Vericel (VCEL), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Schrodinger (SDGR), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Vericel Avadel Pharmaceuticals Structure Therapeutics Schrodinger AbCellera Biologics Janux Therapeutics Arcus Biosciences Syndax Pharmaceuticals Ardelyx Stoke Therapeutics Vericel (NASDAQ:VCEL) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Which has more volatility & risk, VCEL or EOLS? Vericel has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Does the media prefer VCEL or EOLS? In the previous week, Evolus had 2 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Evolus and 1 mentions for Vericel. Vericel's average media sentiment score of 1.76 beat Evolus' score of 1.02 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evolus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VCEL or EOLS more profitable? Vericel has a net margin of 2.85% compared to Evolus' net margin of -22.31%. Vericel's return on equity of 2.47% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Vericel2.85% 2.47% 1.69% Evolus -22.31%-759.04%-24.63% Do insiders and institutionals believe in VCEL or EOLS? 90.7% of Evolus shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 6.1% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend VCEL or EOLS? Vericel presently has a consensus price target of $60.40, indicating a potential upside of 81.68%. Evolus has a consensus price target of $21.25, indicating a potential upside of 228.19%. Given Evolus' higher possible upside, analysts clearly believe Evolus is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Evolus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has better valuation & earnings, VCEL or EOLS? Vericel has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$249.12M6.73$10.36M$0.12277.04Evolus$266.27M1.57-$50.42M-$0.98-6.61 SummaryVericel beats Evolus on 11 of the 16 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$418.80M$10.64B$6.12B$10.57BDividend YieldN/A1.84%5.66%4.70%P/E Ratio-6.6122.2586.0827.08Price / Sales1.5736.13534.29204.46Price / CashN/A25.6126.3031.09Price / Book71.943.4812.726.66Net Income-$50.42M$210.63M$3.30B$275.86M7 Day Performance5.46%2.42%4.34%3.06%1 Month Performance-15.47%2.09%7.82%10.52%1 Year Performance-60.37%-6.89%73.82%33.54% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus4.13 of 5 stars$6.48-0.4%$21.25+228.2%-60.2%$418.80M$266.27M-6.61170Positive NewsVCELVericel3.1622 of 5 stars$31.79+5.2%$60.40+90.0%-25.2%$1.53B$237.22M264.94300Positive NewsAVDLAvadel Pharmaceuticals3.1236 of 5 stars$15.31-0.2%$20.86+36.2%+14.7%$1.49B$169.12M-510.3370GPCRStructure Therapeutics3.0948 of 5 stars$25.30+1.2%$68.67+171.4%-36.5%$1.44BN/A-24.10136SDGRSchrodinger3.3654 of 5 stars$20.04+3.8%$27.83+38.9%+17.6%$1.42B$207.54M-8.08790Analyst DowngradeABCLAbCellera Biologics2.8772 of 5 stars$4.87+2.7%$8.00+64.3%+136.0%$1.42B$28.83M-8.85500JANXJanux Therapeutics2.2508 of 5 stars$23.70+2.0%$78.31+230.4%-46.7%$1.40B$439K-13.1730RCUSArcus Biosciences1.6248 of 5 stars$13.34+3.9%$21.14+58.5%-19.8%$1.37B$258M-4.21500Gap UpSNDXSyndax Pharmaceuticals3.696 of 5 stars$15.56-0.8%$39.22+152.1%-17.1%$1.35B$23.68M-4.00110Analyst RevisionARDXArdelyx4.1073 of 5 stars$5.63+1.6%$11.70+107.8%-22.9%$1.34B$333.61M-24.4890STOKStoke Therapeutics2.704 of 5 stars$24.73+2.4%$25.57+3.4%+116.8%$1.32B$36.56M29.09100Gap Up Related Companies and Tools Related Companies Vericel Competitors Avadel Pharmaceuticals Competitors Structure Therapeutics Competitors Schrodinger Competitors AbCellera Biologics Competitors Janux Therapeutics Competitors Arcus Biosciences Competitors Syndax Pharmaceuticals Competitors Ardelyx Competitors Stoke Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
